Squarepoint’s Pulmonx LUNG Stock Holding History

Squarepoint’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$106K	Buy	82,492 +41,241	+100%	+$68.1K	﹤0.01%	4057
2025 Q4	$91.2K	Buy	+41,251	New	+$77.6K	﹤0.01%	4050
2025 Q3	–	Sell	-12,742	Closed	-$33K	–	4720
2025 Q2	$33K	Buy	12,742 +1,062	+9%	+$4.19K	﹤0.01%	4355
2025 Q1	$78.6K	Sell	11,680 -79,775	-87%	-$565K	﹤0.01%	4273
2024 Q4	$621K	Sell	91,455 -29,682	-25%	-$195K	﹤0.01%	3535
2024 Q3	$1M	Sell	121,137 -23,272	-16%	-$168K	﹤0.01%	2602
2024 Q2	$916K	Buy	144,409 +104,432	+261%	+$803K	﹤0.01%	2617
2024 Q1	$371K	Buy	+39,977	New	+$469K	﹤0.01%	3250
2023 Q1	–	Sell	-82,059	Closed	-$692K	–	3537
2022 Q4	$692K	Buy	82,059 +43,118	+111%	+$410K	﹤0.01%	2080
2022 Q3	$649K	Sell	38,941 -80,745	-67%	-$1.49M	﹤0.01%	2066
2022 Q2	$1.76M	Buy	+119,686	New	+$2.47M	0.01%	1277
2022 Q1	–	Sell	-12,561	Closed	-$403K	–	3236
2021 Q4	$403K	Sell	12,561 -8,359	-40%	-$305K	﹤0.01%	2289
2021 Q3	$753K	Buy	20,920 +14,778	+241%	+$581K	﹤0.01%	1731
2021 Q2	$271K	Buy	+6,142	New	+$267K	﹤0.01%	2604

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's LUNG Position: Q1 2026 in Review

Squarepoint increased its Pulmonx (LUNG) stake by 100% in Q1 2026, buying an estimated $68.1K and bringing the position to 82,492 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #4057.

Squarepoint first reported a position in LUNG in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.76M in Q2 2022. 113 funds tracked by Wall St. Rank hold LUNG as of Q1 2026.

Squarepoint held 82,492 shares of Pulmonx worth $106K as of Q1 2026.
Squarepoint bought 41,241 Pulmonx shares in Q1 2026, an estimated $68.1K.
Pulmonx made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4057 holding.
Squarepoint first reported a position in Pulmonx in Q2 2021 and has held it in 14 quarters since.
Squarepoint's Pulmonx position peaked at $1.76M in Q2 2022.
113 funds tracked by Wall St. Rank held Pulmonx as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.